{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"1.0","value":"1.0"},{"groupId":"OG001","lowerLimit":"0.55","upperLimit":"0.863","value":"0.743"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"description":"Binomial probabilities and their 95% confidence intervals will be used to estimate the response rates (i.e., partial response rate, complete response rate, overall response rate) and event free survival at 2 and 5 years of AVD and brentuximab vedotin for a treatment of patients with stage III/IV HIV-associated Hodgkin lymphoma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nPharmacological Study: Correlative studies\n\nVinblastine: Given IV","id":"OG000","title":"Phase I - Brentuximab 1.2 mg/kg"},{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV","id":"OG001","title":"Phase II - Brentuximab 1.2 m/kg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"5 years","title":"Event-free Survival","type":"SECONDARY","unitOfMeasure":"proportion of participants"}